Trial Profile
ADVATE/ ADYNOVI Hemophilia A Outcome Database
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Octocog alfa (Primary) ; Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Acronyms AHEAD
- Sponsors Baxalta; Baxter Healthcare Corporation; Shire; Takeda
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 22 Mar 2023 Planned End Date changed from 15 Jan 2025 to 16 Jan 2024.
- 22 Mar 2023 Planned primary completion date changed from 15 Jan 2025 to 16 Jan 2024.